JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

C1qtnf6 Expression as a Prognostic Biomarker and Therapeutic Target in Lung Adenocarcinoma: Implications for Immune Infiltration and Tumor Progression

  • 0Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
Cancer Reports (hoboken, N.j.) +

|

June 9, 2025

|

June 9, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

This study reveals that elevated C1qtnf6 expression in lung adenocarcinoma (LUAD) correlates with poor prognosis. Reducing C1qtnf6 inhibits tumor growth and promotes apoptosis, suggesting its potential as a therapeutic target.

Area Of Science

  • Oncology
  • Molecular Biology
  • Cancer Research

Background

  • Lung cancer, particularly lung adenocarcinoma (LUAD), presents a significant global health challenge with increasing incidence and mortality.
  • Aberrant expression of C1qtnf6 has been noted across several human cancers, prompting investigation into its role in tumorigenesis.

Purpose Of The Study

  • To elucidate the functional role of C1qtnf6 in the progression of lung adenocarcinoma (LUAD).
  • To assess the potential of C1qtnf6 as a diagnostic and prognostic biomarker for LUAD.

Main Methods

  • Utilized The Cancer Genome Atlas (TCGA) dataset for analyzing lung cancer data.
  • Performed Kaplan-Meier survival analysis and ROC curve analysis to evaluate C1qtnf6's prognostic and diagnostic value.
  • Conducted in vitro experiments involving C1qtnf6 knockdown in LUAD cell lines to assess effects on proliferation, apoptosis, and Interleukin-10 (IL-10) levels.
  • Employed KEGG and GO pathway analyses to explore molecular mechanisms.

Main Results

  • C1qtnf6 expression was significantly upregulated in LUAD tissues compared to normal tissues.
  • C1qtnf6 expression correlated with immune cell infiltration, the tumor immunological milieu, and response to immune checkpoint blockade and cisplatin treatment.
  • Knockdown of C1qtnf6 led to reduced IL-10 levels, increased apoptosis, and inhibited LUAD cell proliferation, suggesting a link with inflammation.

Conclusions

  • C1qtnf6 may serve as a valuable prognostic biomarker for lung adenocarcinoma.
  • The findings suggest C1qtnf6's involvement in LUAD progression and its potential as a therapeutic target.

Keywords:

Related Concept Videos

lncRNA - Long Non-coding RNAs 02:39

8.5K

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Abnormal Proliferation 02:23

4.5K

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Targeted Cancer Therapies 02:57

7.5K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...